FILANA THERAPEUTICS, INC.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

FLNA$0.45+0.4%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Financial Statements Condensed Consolidated Balance Sheets – September 30, 2026 and December 31, 2025

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited, In thousands, except share and par value data)

	September 30, 2026	December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents	$46,990	$95,502
Restricted cash	31,250	—
Prepaid expenses and other current assets	1,817	2,207
Total current assets	80,057	97,709
Property and equipment, net	20,001	20,646
Total assets	$100,058	$118,355
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued expenses	$40,772	$41,647
Accrued development expense	369	364
Accrued compensation and benefits	648	1,625
Other current liabilities	157	198
Total current liabilities	41,946	43,834
Other non-current liabilities	136	118
Total liabilities	42,082	43,952
Commitments and contingencies (Notes 8, 9 and 10)
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding	—	—
Common stock, $0.001 par value; 120,000,000 shares authorized; 50,067,896 and 48,307,896 shares issued and outstanding at September 30, 2026 and December 31, 2025	50	48
Additional paid-in capital	583,670	570,439
Accumulated deficit	(525,744)	(496,084)
Total stockholders' equity	57,976	74,403
Total liabilities and stockholders' equity	$100,058	$118,355

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.